{
    "root": "34b63ab1-519f-d798-e063-6294a90a76c1",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Enalapril Maleate",
    "value": "20250509",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SODIUM BICARBONATE",
            "code": "8MDF5V39QO"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "ENALAPRIL MALEATE",
            "code": "9O25354EPJ"
        }
    ],
    "indications": null,
    "contraindications": null,
    "warningsAndPrecautions": "Enalapril Maleate Tablets USP, 2.5 mg are yellow colored, round, biconvex tablets. One side scored and engraved with \"T\" above the score and \"2\" below. The other side plain. They are supplied as follows:\n                  NDC: 70518-1339-00\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  \n                  Storage\n                  Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].\n                  Keep container tightly closed.\n                  Protect from moisture.\n                  Dispense in a tight container as per USP, if product package is subdivided.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "Enalapril maleate is contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an angiotensin-converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema.\n                  Do not coadminister aliskiren with enalapril maleate in patients with diabetes (see\n \n  \n                        PRECAUTIONS, Drug Interactions\n                     ).\n\n \n                  Enalapril maleate is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer enalapril maleate within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see\n \n  \n                        WARNINGS, Head and Neck Angioedema\n                     )."
}